Loading...
Loading...
MYGN| Name | Value |
|---|---|
| Revenues | 156.4M |
| Cost of Revenue | 50.4M |
| Gross Profit | 106.0M |
| Operating Expense | 151.0M |
| Operating I/L | -45.0M |
| Other Income/Expense | 0.8M |
| Interest Income | 1.1M |
| Pretax | -44.2M |
| Income Tax Expense | -9.1M |
| Net Income/Loss | -35.1M |
Myriad Genetics, Inc. is a genetic testing and precision medicine company that develops and commercializes molecular diagnostic tests for oncology, women's health, and mental health applications. Their products include DNA sequencing tests such as MyRisk Hereditary Cancer Test, BRACAnalysis CDx Germline Companion Diagnostic Test, and MyChoice CDx Companion Diagnostic Test for assessing cancer risks and determining therapy. They also offer RNA expression tumor analysis tests like Prolaris Prostate Cancer Prognostic Test and EndoPredict Breast Cancer Prognostic Test. Additionally, the company provides prenatal screening tests like Prequel Prenatal Screen and Foresight Carrier Screen, as well as the GeneSight Psychotropic Mental Health Medication Test for aiding drug selection in mental health conditions.
